Developing a SARS-CoV-2 Vaccine at Warp Speed

August 4, 2020, Vol 324, No. 5, Pages 419-524


Developing a SARS-CoV-2 Vaccine at Warp Speed
Kevin P. O’Callaghan, MB, BCh, BAO; Allison M. Blatz, MD; Paul A. Offit, MD
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):437-438. doi:10.1001/jama.2020.12190
This Viewpoint discusses the mechanisms of the 5 leading COVID-19 vaccine candidates—2 messenger RNA vaccines, 1 recombinant VSV vector product, and 2 replication-defective adenovirus vector approaches—and emphasizes the need to demonstrate safety as well as efficacy to facilitate broad uptake by the public.
As the COVID-19 pandemic continues to cause significant disruption to both the physical and economic health of the world’s population, pathways of vaccine development are adapting in ways that could not have been predicted even a year ago. The rapid identification of immunogenic targets of a novel coronavirus, the leveraging of experimental vaccine platforms, and the tragic nature of an ongoing pandemic have created a fertile breeding ground for innovation. Although the ultimate success of a vaccine candidate, or candidates, remains unknown, the changes in the field of vaccinology that these exigent circumstances have brought are likely here to stay.
:: Audio Author Interview: Coronavirus Vaccine Development
:: Conversations with Dr Bauchner: Coronavirus Update With Eric Topol, MD